Now Is A Suitable Moment For A Long-Term Purchase Of Agenus Inc. (NASDAQ: AGEN)

0
154

RTW Investments LP recently announced the acquisition of new stake in Agenus Inc. (NASDAQ:AGEN). The institutional investor has increased its shareholding in the Healthcare company by 47.54% to 13.1 million shares with purchase of 4.22 million shares. This fresh investment now brings its stake to 7.71% valued currently at $51.47 million. In addition, Cormorant Asset Management LP raised its holdings by 12.17 million to 12.17 million shares. And The Vanguard Group, Inc. has lifted its position by 0.69% or 37903.0 shares – to 5.55 million shares.

With over 2.12 million Agenus Inc. (AGEN) shares trading Friday and a closing price of $3.19 on the day, the dollar volume was approximately $6.77 million. The shares have shown a negative weekly performance of -14.11% and its price on 07/24/20 lost nearly -1.39%. Currently, there are 145.06M common shares owned by the public and among those 139.27M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for AGEN have a consensus price objective of $5.50. The analysts have set the share’s price value over the next 12 months at a high of $6.00 and a low of $5.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Agenus Inc. stock is 1.30 for the next 12 months. But an upside of 46.83% will see the stock hit the forecast high price target while mean target price for the stock is $5.50.

Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in Agenus Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 4.18 million shares of the company’s stock, all valued at over $16.42 million. The company bought an additional 85699.0 shares recently to bring their total holdings to about 2.46% of the shares outstanding. Vanguard Total Stock Market Index bought 0.77 million shares to see its total holdings expand to 4.01 million shares valued at over $15.76 million and representing 2.36% of the shares outstanding. iShares Russell 2000 ETF sold 72240.0 shares to bring its total holdings to over 2.85 million shares at a value of $11.19 million. iShares Russell 2000 ETF now owns shares totaling to 1.68% of the shares outstanding.

Shares of Agenus Inc. (NASDAQ: AGEN) opened at $3.42, up $0.18 from a prior closing price of $3.24. However, the script later closed the day at $3.19, down -1.39%. The company’s stock has a 5-day price change of -14.11% and 12.50% over the past three months. AGEN shares are trading -21.50% year to date (YTD), with the 12-month market performance up to 33.12% higher. It has a 12-month low price of $1.82 and touched a high of $4.78 over the same period. Currently, 2.12 million shares have been traded, compared to an average intraday trading volume of 3.19 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -14.80%, -9.95%, and -2.74% respectively.

Institutional ownership of Agenus Inc. (NASDAQ: AGEN) shares accounts for 46.70% of the company’s 145.06M shares outstanding. Mutual fund holders own 13.89%, while other institutional holders and individual stakeholders account for 32.35% and 12.32% respectively.

It has a market capitalization of $569.19M and a beta (3y monthly) value of 1.99. The earnings-per-share (ttm) stands at -$1.23. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.40% over the week and 5.38% over the month.

Analysts forecast that Agenus Inc. (AGEN) will achieve an EPS of -$0.27 for the current quarter, -$0.27 for the next quarter and -$1.05 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.32 while analysts give the company a high EPS estimate of -$0.23. Comparatively, EPS for the current quarter was -$0.38 a year ago. Earnings per share for the fiscal year are expected to increase by 44.60%, and 0.00% over the next financial year.

If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate Agenus Inc. (AGEN) as a “Strong Buy” at a consensus score of 1.30. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the AGEN, a number of firms have released research notes about the stock. B. Riley FBR stated their Buy rating for the stock in a research note on November 19, 2019, with the firm’s price target at $6. B. Riley FBR coverage for the Agenus Inc. (AGEN) stock in a research note released on April 22, 2019 offered a Buy rating with a price target of. H.C. Wainwright was of a view on October 28, 2016 that the stock is Neutral, while Maxim Group gave the stock Buy rating on October 27, 2016, issuing a price target of. Maxim Group on their part issued Buy rating on March 11, 2016.

LEAVE A REPLY

Please enter your comment!
Please enter your name here